EUCTR2010-021125-12-LT进行中（未招募）1 期
Early access of TMC207 in combination with other anti-tuberculosis (TB) drugs in subjects with extensively drug resistant (XDR) or pre-XDR pulmonary TB
Janssen Infectious Diseases BVBA0 个研究点目标入组 295 人开始时间: 2011年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 295
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subject with confirmed pulmonary XDR or pre-XDR-TB infection with resistance to INH, RMP, and to a FQ and/or injectable 2nd line TB drug (kanamycin, amikacin, or capreomycin). Confirmation should include previous (within the preceding 6 months) smear or culture and DST results demonstrating pulmonary TB with an XDR or pre-XDR resistance pattern.
- •2. Subject has limited or no treatment options and is unable/ineligible to participate in any other TMC207 study.
- •3. Aged = 18 years.
- •4. Subject will be managed at a medical center that has been certified by the Green Light Committee of the WHO Stop TB Partnership, OR, following an assessment of the site confirms that the site meets equivalent standards, including DOTS-Plus-equivalent supervision of medication administration; laboratory capacity to provide regular sputum cultures and drug susceptibility tests (DST); and an uninterrupted supply of approved second line drugs with which to create a companion BR.
- •5. Medically stable in the opinion of the investigator on the basis of physical examination, and safety examinations performed at screening.
- •6. All women of childbearing potential must have a negative urine pregnancy test at screening.
- •7. Women must:
- •– be postmenopausal for at least 2 years, or
- •– be surgically sterile (have had a total hysterectomy or bilateral oophorectomy, tubal ligation/bilateral tubal clips without reversal operation, or otherwise be incapable of
- •pregnancy), or
- •– not be heterosexually active for the duration of the early access study, or
- •– be practicing a highly effective method of birth control (as specified below), and agree to continue to use the same method of contraception throughout TB treatment:
- •? Use a double barrier method (i.e., male condom + either diaphragm or cervical cap),
- •? Use non-estrogen hormonal based contraceptives in combination with a barrier
- •contraceptive (i.e., male condom, diaphragm or cervical cap, or femal condom), or
- •? Use an intrauterine device in combination with a barrier contraceptive (i.e., male condom, diaphragm or cervical cap, or female condom).
- •Note: A male and female condom should not be used together due to risk of breakage or damage caused by latex friction.
- •8. Men must agree to use a highly effective method of birth control (i.e., male condom with either female intrauterine device, diaphragm, cervical cap or [non-estrogen] hormonal based contraceptives) and not to donate sperm during the early access study and for 3 months after receiving the last dose of TB treatment.
- •Note: A male and female condom should not be used together due to risk of breakage or damage caused by latex friction.
- •9. Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the early access study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 290
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1. History of and/or clinically relevant, currently active or underlying gastrointestinal, cardiovascular, nervous system, psychiatric, metabolic, renal, respiratory (other than due to TB), inflammatory, neoplastic, skin, immunological or infectious disease, which is not stable and controlled.
- •If there are clinically relevant, currently active or underlying diseases, they should not compromise the safety of the subject or the ability to participate in the study as judged by the investigator. The investigator is encouraged to discuss concomitant illnesses with the sponsor.
- •2. Subjects with complicated or severe extra pulmonary manifestations of TB, including osteoarticular and central nervous system infection.
- •3. HIV-infected subjects who cannot be treated with antiretroviral (ARVs) regimens as outlined in Section 4.4 during administration of TMC207.
- •4. Having received TMC207 in a previous study.
- •5. Subject is eligible for other Tibotec sponsored TMC207 studies.
- •6. Known allergies, hypersensitivity, or intolerance to TMC207 or its excipients.
- •7. Use of disallowed therapies as specified in the section of disallowed medication (see Section 8). 8. Are currently enrolled in another investigational study or have been enrolled in an
- •investigational study within 60 days before the planned start of treatment with TMC207, unless approved by the sponsor.
- •9. Pregnant or breast-feeding.
- •10. Any condition that, in the opinion of the investigator, would compromise the early access study or the well-being of the subject or prevent the subject from meeting or performing protocol requirements.
- •11. Current alcohol, barbiturate, amphetamine, recreational or narcotic drug use, which in the investigator’s opinion would compromise subject’s safety and/or compliance with the protocol procedures.
- •12. Subjects with the following laboratory abnormalities at screening as defined by the DMID Adult Toxicity Table and in accordance with the normal ranges of the clinical laboratory at the site:
- •- serum creatinine grade 1 or greater (> 1.0 x ULN);
- •- lipase grade 2 (with no signs or symptoms of pancreatitis) or greater (> 1.5 x ULN);
- •- AST or ALT grade 2 or greater (= 2.0 - < 3.0 x ULN);
- •- total bilirubin grade 1 or greater (> 1.0 x ULN).
- •Note: If the results of the serum chemistry panel, hematology, or urinalysis are outside the normal reference ranges (including the above listed parameters), the subject may be included only if the investigator judges the abnormalities or deviations from normal to be not clinically relevant or to be appropriate and reasonable for the population under study. This determination must be recorded in the subject's source documents and initialed by the investigator.
- •13. Subjects with QTcF interval > 450 msec at screening (and, if above the limit, confirmed by repeat single ECG).
- •14. Subjects with any other clinically significant ECG abnormality at screening, such as arrhythmia, ischemia, or evidence of heart failure.
- •15. Subjects with a family history of Long QT Syndrome.
- •16. Vulnerable subjects (e.g., persons kept in detention).
研究者
相似试验
进行中（未招募）
不适用
未命名试验EUCTR2006-002499-16-DEJanssen R&D Ireland
已完成
不适用
Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options.HIV-110047438NL-OMON30522Janssen-Cilag120
进行中（未招募）
不适用
Early Access of TMC125 in combination with other antiretrovirals in treatment-experienced HIV-1 infected subjects with limited treatment options. - NDEUCTR2006-002499-16-ITTIBOTEC PHARMACEUTICALS LTD.5,000
进行中（未招募）
不适用
Safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen in MDR-TB (Multi-drug Resistant Tuberculosis).EUCTR2008-008444-25-EEJanssen Infectious Diseases BVBA225
进行中（未招募）
不适用
Safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen in MDR-TB (Multi-drug Resistant Tuberculosis).Sputum smear-positive pulmonary multi-drug resistant tuberculosisMedDRA version: 14.1Level: PTClassification code 10044755Term: TuberculosisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-008444-25-LVJanssen Infectious Diseases BVBA225